Page 3 - Inhalation Solution News Today

/PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation with a purpose to provide a brighter future for patients, today...

/PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) today announced its financial results for the quarter ended June 30, 2021. Total revenue in the...

Read more about Nifty hits record high; breadth strong on Business Standard. Key benchmark indices are trading higher in early trade on buying demand in index pivotals. At 9:25 IST, the barometer index, the S&P BSE Sensex, was up 82.75 points or 0.16% at 52,315.18. The Nifty 50 index was up 21.35 points or 0.14% at

Stocks to watch out for today: Standard Industries, Lupin, KP Energy, Confidence Petroleum, and Cadila Healthcare

Read more about Stocks to watch: M&M, PNB, Bharat Forge, Lupin, rate sensitive stocks on Business Standard. ABB Power Products on Thursday said it has resumed operations at its manufacturing facility in Bengaluru from May 28

Read more about Lupin launches authorized generic version of Brovana in US on Business Standard. Lupin announced the launch of the authorized generic version of Brovana (arformoterol tartrate) Inhalation Solution 15 mcgꝉ/2 mL, unit-dose vials, of Sunovion Pharmaceuticals Inc.

Read more about Bharti Airtel, M&M, Lupin in focus on Business Standard. Bharti Airtel informed that ICRA has reaffirmed [ICRA]AA- (Stable) issuer rating of the company. However, since the company, presently has no instrument rated under this rating, ICRA has withdrawn this rating at companys request.

Message : Required fields SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., May 5, 2021 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) today announced its financial results for the quarter ended March 31, 2021. Total revenue in the first quarter of 2021 grew 6% year over year to $379.1 million, compared to $356.3 million in the first quarter of 2020. "2021 is already a historic year for United Therapeutics, with the recent FDA approval and launch of Tyvaso for treatment of...

United Therapeutics Corporation Reports First Quarter 2021 Financial Results Tyvaso® (treprostinil) Inhalation Solution approved for pulmonary hypertension associated with interstitial lung disease (PH-ILD) Tyvaso DPI™ New Drug Application (NDA) submitted to U.S. Food and Drug Administration TETON study of Tyvaso in idiopathic pulmonary fibrosis (IPF) expected to enroll its first patients in the second quarter of 2021 News provided by Share this article Share this article SILVER SPRING, Md. ...

United Therapeutics Announces FDA Approval and Launch of Tyvaso® for the Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease First and only approved therapy in the United States for patients with PH-ILD, a serious, life-threatening disease with potentially more than 30,000 patients in need FDA approval based on data from the INCREASE clinical trial PH-ILD is the second FDA-approved indication for Tyvaso, which was initially approved for the treatment of pulmonary arte...